NEW YORK (GenomeWeb) – BioMérieux and Sysmex announced today that they will dissolve a nearly 10-year-old joint venture that aimed to bring BioMérieux's in vitro diagnostic products to the Japanese market.
No reason was given for the dissolution.
In early 2008, the companies formed the JV, called Sysmex BioMérieux, to promote and commercialize BioMérieux's IVD reagents and medical instruments in Japan through Sysmex's sales and marketing infrastructure. Sysmex held a 34 percent stake in the JV, with BioMérieux owning the remaining 66 percent.
However, the companies have now agreed to dissolve the JV, transferring all of Sysmex's holdings in the company to BioMérieux. Sysmex will continue to distribute BioMérieux products in Japan until Oct. 31 and provide customer service for these products until March 31, 2018. BioMérieux said that it intends to build its own commercial structure in Japan to take over activities previously handled by Sysmex.
Additional terms were not disclosed.